Open Orphan #ORPH presents at Total Market Solutions & Proactive Investors’ One2One Forum, London

Open Orphan, a European-focussed, rare and orphan drug consulting services platform, is pleased to announce that on Wednesday 18th September the Company will be attending and presenting at Total Market Solutions, Moorgate, at 12:30pm and will also be attending and presenting at Proactive Investors’ One2One Forum at Chesterfield Mayfair Hotel, London, W1J 5EB from 18:00 onwards. Cathal Friel, Open Orphan’s Chief Executive Officer, will be in […]

Open Orphan (ORPH) CEO Cathal Friel tells Alan Green why he expects 40 percent growth year on year

https://audioboom.com/posts/7361662-open-orphan-orph-ceo-cathal-friel-tells-alan-green-why-he-expects-40-percent-growth-year-on-year Open Orphan (ORPH) CEO Cathal Friel tells Alan Green why he expects 40 percent growth year on year. Open Orphan (ORPH) currently trades on just 1x revenues & a market cap of just £15m. CEO Cathal Friel tells Alan Green why he expects to see his company, into which he’s invested £2m of his […]

Open Orphan (ORPH) Upcoming Investor Events

Open Orphan, a European-focussed, rare and orphan drug consulting services platform, is pleased to announce that the Company will be attending and presenting at a series of investor events from the 4thSeptember to 10th October 2019. Cathal Friel, Open Orphan’s Chief Executive Officer, will be in attendance for all of the events and will be presenting […]

Open Orphan Plc (ORPH) Directorate Changes

Open Orphan, a European-focussed, rare and orphan drug consulting services platform, is pleased to announce the appointment to the board of David Kelly as an Independent Non-Executive Director. David has extensive orphan drug company experience both in Europe and in the USA. He was Executive Vice President and Managing Director of Ireland at Horizon Therapeutics […]

Open Orphan PLC (ORPH) Exercise of Warrants and Issue of Shares

Open Orphan, a European-focussed, rare and orphan drug consulting services platform, announces that the Company has received notices of exercise of warrants over 539,654 ordinary shares of 0.1 pence each in the capital of the Company (“Ordinary Shares”) at a price of 0.1 pence per share for 191,051 ordinary shares and at a price of […]

Open Orphan (ORPH) Chief Executive Officer, Cathal Friel discuss an operational update on the Vox Markets Podcast with Justin Waite

Click here to listen to the interview Open Orphan plc is a European-focussed, rare and orphan drug consulting services platform. The Company consists of four elements: a European clinical research organisation and consultancy; an orphan drug services business; a Virtual Rep and Data Access Platform consisting of physicians and key opinion leaders; and a Health […]

Open Orphan (ORPH) sells its remaining shareholding in Integumen plc

Open Orphan, a European-focussed, rare and orphan drug consulting services platform, announces that it has now sold its remaining shareholding in Integumen plc following its disposal of 30,071,428 ordinary shares. The total proceeds of the sale are £566,846. This completes the process begun with the divestment of Innovenn UK limited to Integumen plc in November 2016. The […]